Dendritic cell immunotherapy for glioblastoma.
Dendritic cell immunotherapy is emerging as a promising addition to the multimodal treatment of patients with glioblastoma multiform. Initial Phase I and II trials have demonstrated favorable outcomes with minimal toxicity. In this editorial, the current status and the future challenges of this therapy are discussed.
Department of Neurosurgery, King's College Hospital, Denmark Hill London, SE5 9RS, UK.
Stavros
S
Polyzoidis
Keyoumars
K
Ashkan
D014408:Biomarkers, Tumor / Q000276:immunology; D001932:Brain Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D019496:Cancer Vaccines / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003713:Dendritic Cells / Q000276:immunology*; D005909:Glioblastoma / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D011878:Radiotherapy
D014408:Biomarkers, Tumor; D019496:Cancer Vaccines
dendritic cell; glioblastoma multiforme; immunotherapy; overall survival; side-effect